Print this page    •   Back to Web version of article

Entecavir in Hepatitis B Virus (HBV)/HIV Co-Infected Patients
Supplement to the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents -- October 10, 2006

April 30, 2007

Previously, the guidelines recommended entecavir as an option for patients who required treatment for Hepatitis B virus (HBV) but not HIV infection. This recommendation was based on in vitro data showing no significant activity of entecavir against HIV-1.1 A recent case series of three patients who received entecavir without concomitant antiretroviral therapy reported a 1 log10 decline in HIV-RNA levels and emergence of M184V mutations in one patient who was studied in detail.2

Based on these preliminary findings, the Panel recommends that:

For HBV/HIV co-infected patients, entecavir should not be used for the treatment of HBV infection without concomitant treatment for HIV.

References

  1. Baraclude (Product Labelling, Bristol-Myers Squibb). March 2005.
  2. McMahon M, Jilek B, Brennan T, et al. The anti-hepatitis B drug entecavir inhibits HIV-1 replication and selects HIV-1 variants resistant to antiretroviral drugs. 14th Conference on Retroviruses and Opportunistic Infections; Feb 25-28, 2007; Los Angeles, CA. Abstract 136LB.



This article was provided by AIDSinfo. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/treat/art40845.html

General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.